Related Experiment Video
Updated: May 21, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Childhood nephrotic syndrome--current and future therapies
Larry A Greenbaum1, Rainer Benndorf, William E Smoyer
1Emory University, Atlanta, GA 30322, USA.
Insights
Corticosteroids are standard for childhood nephrotic syndrome, but some children are resistant. New treatments targeting podocyte dysfunction are needed for steroid-resistant nephrotic syndrome to prevent kidney failure.
Area of Science:
- Pediatric Nephrology
- Molecular Medicine
- Immunology
Background:
- Corticosteroids significantly improved outcomes for childhood nephrotic syndrome over 50 years ago.
- A substantial portion of children with nephrotic syndrome are steroid-resistant, risking progression to end-stage renal disease.
- Current treatments for steroid-resistant nephrotic syndrome include immunosuppressive agents like ciclosporin and tacrolimus.
Purpose of the Study:
- To review current treatments for childhood nephrotic syndrome.
- To discuss novel therapeutic pathways targeting podocytes for future treatments.
- To challenge the traditional immune theory of nephrotic syndrome pathogenesis.
Main Methods:
- Literature review of current and emerging treatments for childhood nephrotic syndrome.
- Analysis of evidence implicating podocyte dysfunction in nephrotic syndrome.
- Discussion of potential molecular targets in podocytes for next-generation therapies.
Main Results:
- Corticosteroids are the primary treatment, but steroid resistance remains a significant clinical challenge.
- Emerging evidence suggests podocyte dysfunction, not solely T-cell mediated immunity, underlies nephrotic syndrome.
- Conventional immunosuppressants like glucocorticoids and ciclosporin directly impact podocyte function.
Conclusions:
- Novel therapeutic strategies for steroid-resistant nephrotic syndrome should focus on podocyte-targeted therapies.
- Understanding podocyte biology is crucial for developing next-generation treatments.
- Future research should explore pathways to restore podocyte integrity and function in pediatric nephrotic syndrome.
Abstract:
The introduction of corticosteroids more than 50 years ago dramatically improved the prognosis of children with nephrotic syndrome. Corticosteroids remain the standard initial treatment for children with this disease, but a considerable proportion of patients do not respond and are therefore at risk of progressing to end-stage renal disease. Because of this risk, new therapeutic strategies are needed for steroid-resistant nephrotic syndrome. These strategies have historically focused on identifying effective alternative immunosuppressive agents, such as ciclosporin and tacrolimus, yet evidence now indicates that nephrotic syndrome results from podocyte dysfunction. Even conventional immunosuppressive agents, such as glucocorticoids and ciclosporin, directly affect podocyte structure and function, challenging the 'immune theory' of the pathogenesis of childhood nephrotic syndrome in which disease is caused by T cells. This Review summarizes the currently available treatments for childhood nephrotic syndrome, and discusses selected novel pathways in podocytes that could be targeted for the development of next-generation treatments for children with this syndrome.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care

